Search

Your search keyword '"Anwer, Faiz"' showing total 1,158 results
Start Over Author "Anwer, Faiz" Search Limiters Available in Library Collection
1,158 results on '"Anwer, Faiz"'

2. Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy

Author

Dima, Danai, Abdallah, Al-Ola, Davis, James A., Awada, Hussein, Goel, Utkarsh, Rashid, Aliya, DeJarnette, Shaun, Anwer, Faiz, Shune, Leyla, Raza, Shahzad, Mahmoudjafari, Zahra, Williams, Louis, Faiman, Beth, McGuirk, Joseph P., Sauter, Craig S., Ahmed, Nausheen, Khouri, Jack, and Hashmi, Hamza

Published
2024
Full Text
View/download PDF

10. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience

Author

Khouri, Jack, Dima, Danai, Li, Hong, Hansen, Doris, Sidana, Surbhi, Shune, Leyla, Anwer, Faiz, Sborov, Douglas, Wagner, Charlotte, Kocoglu, Mehmet H., Atrash, Shebli, Voorhees, Peter, Peres, Lauren, Hovanky, Vanna, Simmons, Gary, Williams, Louis, Raza, Shahzad, Afrough, Aimaz, Anderson, Larry D., Jr, Ferreri, Christopher, Hashmi, Hamza, Davis, James, McGuirk, Joseph, Goldsmith, Scott, Borogovac, Azra, Lin, Yi, Midha, Shonali, Nadeem, Omar, Locke, Frederick L., Baz, Rachid, Hamilton, Betty, Alsina, Melissa, Sauter, Craig, Patel, Krina, and Kaur, Gurbakhash

Published
2024
Full Text
View/download PDF

11. Current Novel Targeted Therapeutic Strategies in Multiple Myeloma

Author

Lin, Cindy Hsin-Ti, primary, Tariq, Muhammad Junaid, additional, Ullah, Fauzia, additional, Sannareddy, Aishwarya, additional, Khalid, Farhan, additional, Abbas, Hasan, additional, Bader, Abbas, additional, Samaras, Christy, additional, Valent, Jason, additional, Khouri, Jack, additional, Anwer, Faiz, additional, Raza, Shahzad, additional, and Dima, Danai, additional

Published
2024
Full Text
View/download PDF

14. Comparative Meta-Analysis of Triplet vs. Quadruplet Induction Regimens in Newly Diagnosed, Treatment Naïve, Multiple Myeloma.

Author

Paul, Barry, Anwer, Faiz, Raza, Shahzad, Mammadzadeh, Aytaj, Khasawneh, Bayan, Shatnawi, Sara, McGuirk, Joseph, Ahmed, Nausheen, Mahmoudjafari, Zahra, Mushtaq, Muhammad, Abdallah, Al-Ola, and Atrash, Shebli

Subjects
*THERAPEUTIC use of antineoplastic agents, *MULTIPLE myeloma diagnosis, *THERAPEUTIC use of monoclonal antibodies, *MULTIPLE myeloma, *DRUG toxicity, *DRUG side effects, *ANTINEOPLASTIC agents, *META-analysis, *DESCRIPTIVE statistics, *PROGRESSION-free survival, *CONFIDENCE intervals, *INDUCTION chemotherapy, *OVERALL survival
Abstract

Simple Summary: Induction regimens using 4-drugs for patients with newly diagnosed multiple myeloma have shown impressive results in multiple trials. However, trials of 4-drug regimens typically use a 3-drug regimen as their comparator, which limits our ability to determine whether the benefit is from the specific combination of drugs or just the addition of more agents. We performed a meta-analysis to compare all trials that compared 4-drug to 3-drug regimens and found that the addition of an anti-CD38 antibody (daratumumab or isatuximab) resulted in improved responses, while 4-drug regimens without an anti-CD38 antibody performed similarly to 3-drug regimens. While the addition of an anti-CD38 antibody led to increased adverse effects, these were predominantly mild and easily managed. These data suggest that an anti-CD38 antibody should be part of all 4-drug induction regimens for newly diagnosed myeloma patients. The use of 4-drug induction regimens for treatment naïve newly diagnosed multiple myeloma (NDMM) is associated with improved depth of response and progression-free survival (PFS). However, head-to-head trials of 4-drug combinations are lacking, and instead, these regimens are typically compared to 3-drug backbones; limiting the ability to discern whether any additional benefit (or toxicity) is simply additive or represents a synergy (or interaction). We conducted a meta-analysis of phase 2 and phase 3 clinical trials that randomized treatment naïve NDMM patients to either a 4-drug or 3-drug induction regimen. We included 11 trials which represented 6509 unique patients. PFS for all trials in the meta-analysis was 54 months with a 4-drug induction and 8.9 months with a 3-drug induction (HR: 0.49; 95% CI: 0.45; 0.54), but there was no benefit to using a 4-drug induction that did not include an anti-CD38 antibody (PFS 4-drug 8.1 months, PFS 3-drug 8.0 months; HR 0.95; 95% CI 0.86; 1.06). Adverse events were more frequent with the quadruplet regimens but were predominately mild. High-grade (≥3) adverse events (AEs) that were more common with 4-drug regimens were infections (RR: 1.34; 95% CI 1.17; 1.54) and thrombocytopenia (RR: 1.39; 95% CI 1.12; 1.74). This study suggests that 4-drug induction regimens which include an anti-CD38 antibody improve efficacy although with additional toxicity in NDMM patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. The TACTUM23 Study: Access to Cellular Therapies in Multiple Myeloma: Perspectives of Treating Versus Referring Physicians in 2023

Author

Atallah, Rawan, primary, Saif, Md Saiful Islam, additional, Danai, Dima, additional, Shrestha, Anuj, additional, Anwer, Faiz, additional, Mushtaq, Muhammad Umair, additional, Lutfi, Forat, additional, Shune, Leyla, additional, Hashmi, Hamza, additional, Ganguly, Siddhartha MD, additional, McGuirk, Joseph P, additional, Atrash, Shebli, additional, Abdallah, Al-Ola, additional, Banerjee, Rahul, additional, Ahmed, Nausheen, additional, and Logan, Emerson, additional

Published
2024
Full Text
View/download PDF

22. Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Not Meeting the Karmma-1 Trial Eligibility Criteria: A Real-World Multicenter Study from the US Myeloma Innovations Research Collaborative (USMIRC)

Author

Dima, Danai, primary, Rashid, Aliya, additional, Davis, James, additional, Awada, Hussein, additional, Abdallah, Al-Ola, additional, DeJarnette, Shaun, additional, Shune, Leyla, additional, Khouri, Jack, additional, Hashmi, Hamza, additional, McGuirk, Joseph P, additional, Anwer, Faiz, additional, and Ahmed, Nausheen, additional

Published
2024
Full Text
View/download PDF

23. A Multicenter Experience: Duration of Mandatory CRS and Icans Monitoring for Myeloma and Lymphoma CAR-T Recipients

Author

Wesson, William, primary, Dima, Danai, additional, Davis, James, additional, Rashid, Aliya, additional, Furqan, Fateeha, additional, Saif, Md Saiful Islam, additional, Logan, Emerson, additional, McGann, Mary, additional, Tabak, Carine, additional, Hazlett, Liz, additional, Lutfi, Forat, additional, Mushtaq, Muhammad Umair, additional, Hoffmann, Marc, additional, Abdallah, Al-Ola, additional, Anwer, Faiz, additional, Hamadani, Mehdi, additional, McGuirk, Joseph P, additional, Hashmi, Hamza, additional, and Ahmed, Nausheen, additional

Published
2024
Full Text
View/download PDF

25. Neighborhood Socioeconomic Disadvantage and Distance from Treatment Center Do Not Impact Survival Outcomes of Patients with Non-Hodgkin's Lymphoma (NHL) and Multiple Myeloma (MM) Treated with CAR T-Cell Therapies.

Author

Mian, Agrima, primary, Dima, Danai, additional, Hamilton, Betty K., additional, Winter, Allison, additional, Khouri, Jack, additional, Williams, Louis, additional, Raza, Shahzad, additional, Jagadeesh, Deepa, additional, Gerds, Aaron T., additional, Dean, Robert M., additional, Sobecks, Ronald M., additional, Kalaycio, Matt E., additional, Brunstein, Claudio G., additional, Sauter, Craig S, additional, Anwer, Faiz, additional, Hill, Brian T., additional, and Caimi, Paolo, additional

Published
2024
Full Text
View/download PDF

26. Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy and Teclistamab in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease: A Real-World Experience of the US Myeloma Innovations Research Collaborative (USMIRC)

Author

Dima, Danai, primary, Davis, James, additional, Ahmed, Nausheen, additional, Sannareddy, Aishwarya, additional, Shaikh, Hira, additional, Shune, Leyla, additional, Kaur, Gurbakhash, additional, Khouri, Jack, additional, Afrough, Aimaz, additional, Strouse, Christopher Sun, additional, Lochner, Jonathan, additional, Mahmoudjafari, Zahra, additional, Raza, Shahzad, additional, Valent, Jason, additional, Anderson, Larry D., additional, Anwer, Faiz, additional, Hashmi, Hamza, additional, and Abdallah, Al-Ola, additional

Published
2024
Full Text
View/download PDF

29. Single-Agent Cyclosporine for Graft-versus-Host Disease Prophylaxis in Patients with Acquired Aplastic Anemia Receiving Fludarabine-Based Conditioning

Author

Iftikhar, Raheel, Chaudhry, Qamar un Nisa, Mahmood, Syed Kamran, Ghafoor, Tariq, Satti, Humayun Shafique, Shahbaz, Nighat, Khan, Mehreen Ali, Khattak, Tariq Azam, Shamshad, Ghassan Umair, Rehman, Jahanzeb, Farhan, Muhammad, Humayun, Saima, Risalat, Amina, Wahab, Ahsan, Satti, Tariq Mehmood, Anwer, Faiz, and Ahmed, Parvez

Published
2020
Full Text
View/download PDF

32. Incidence and Risk of Secondary Malignancy in Patients with Waldenström Macroglobulinemia: A Population-Based Analysis

Author

Rehman, Mohammad Ebad Ur, primary, Hameed, Maha, additional, Shah, Zunairah, additional, Ashruf, Omer S, additional, Ali, Rabia, additional, Faraz, Fatima, additional, Basit, Jawad, additional, Khan, Israr, additional, Fazal, Faizan, additional, Iftikhar, Ahmad, additional, Nashwan, Abdulqadir J, additional, Faisal, Muhammad Salman, additional, and Anwer, Faiz, additional

Published
2024
Full Text
View/download PDF

33. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience

Author

Dima, Danai, primary, Davis, James A., additional, Ahmed, Nausheen, additional, Jia, Xuefei, additional, Sannareddy, Aishwarya, additional, Shaikh, Hira, additional, Shune, Leyla, additional, Kaur, Gurbakhash, additional, Khouri, Jack, additional, Afrough, Aimaz, additional, Strouse, Christopher, additional, Lochner, Jonathan, additional, Mahmoudjafari, Zahra, additional, Raza, Shahzad, additional, Valent, Jason, additional, Anderson, Larry D., additional, Anwer, Faiz, additional, Abdallah, Al-Ola, additional, and Hashmi, Hamza, additional

Published
2023
Full Text
View/download PDF

34. Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma

Author

Davis, James A., primary, Dima, Danai, additional, Ahmed, Nausheen, additional, DeJarnette, Shaun, additional, McGuirk, Joseph, additional, Jia, Xuefei, additional, Raza, Shahzad, additional, Khouri, Jack, additional, Valent, Jason, additional, Anwer, Faiz, additional, Abdallah, Al-Ola, additional, and Hashmi, Hamza, additional

Published
2023
Full Text
View/download PDF

36. Outcome of Fludarabine-Based Conditioning in High-Risk Aplastic Anemia Patients Undergoing Matched Related Donor Transplantation: A Single-Center Study from Pakistan

Author

Chaudhry, Qamar un Nisa, Iftikhar, Raheel, Satti, Tariq Mehmood, Mahmood, Syed Kamran, Ghafoor, Tariq, Shamshad, Ghassan Umair, Farhan, Muhammad, Shahbaz, Nighat, Khan, Mehreen Ali, Khattak, Tariq Azam, Rehman, Jahanzeb, Humayun, Saima, Satti, Humayoon Shafique, Anwer, Faiz, and Ahmed, Parvez

Published
2019
Full Text
View/download PDF

37. Comparison of Conventional Cyclophosphamide versus Fludarabine-Based Conditioning in High-Risk Aplastic Anemia Patients Undergoing Matched-Related Donor Transplantation

Author

Iftikhar, Raheel, Chaudhry, Qamar un Nisa, Satti, Tariq Mehmood, Mahmood, Syed Kamran, Ghafoor, Tariq, Shamshad, Ghassan Umair, Shahbaz, Nighat, Khan, Mehreen Ali, Khattak, Tariq Azam, Rehman, Jahanzeb, Farhan, Muhammad, Humayun, Saima, Haq, Humera, Naqvi, Syeda Ammaara Anwaar, Anwer, Faiz, Satti, Humayoon Shafique, and Ahmed, Parvez

Published
2020
Full Text
View/download PDF

38. Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction

Author

Fraz, Muhammad Asad, Warraich, Faiza Hassan, Warraich, Sami Ullah, Tariq, Muhammad Junaid, Warraich, Zabih, Khan, Ali Younas, Usman, Muhammad, Ijaz, Awais, Tenneti, Pavan, Mushtaq, Adeela, Akbar, Faisal, Shahid, Zaina, Ali, Zeeshan, Fazeel, Hafiz Muhammad, Rodriguez, Cesar, Nasar, Aboo, McBride, Ali, and Anwer, Faiz

Published
2019
Full Text
View/download PDF

41. Management of Adverse Reactions for BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused Review

Author

Khanam, Razwana, primary, Faiman, Beth, additional, Batool, Saba, additional, Najmuddin, Mohammed Musa, additional, Usman, Rana, additional, Kuriakose, Kiran, additional, Ahmed, Arooj, additional, Rehman, Mohammad Ebad Ur, additional, Roksana, Zinath, additional, Syed, Zain, additional, Anwer, Faiz, additional, and Raza, Shahzad, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results